DR. RICHARD MICHAEL CARLTON, M.D.
Psychiatric at Secor Dr, Port Washington, NY
License number
New York 106449
Category
Psychiatric
Type
Psychiatry
Address
Address
3 Secor Dr, Port Washington, NY 11050
Phone
(516) 944-5529
(516) 944-7010 (Fax)
(516) 944-7010 (Fax)
Professional information
Bacteriophage Genotypically Modified To Delay Inactivations By The Host Defense System
US Patent:
5811093, Sep 22, 1998
Filed:
Apr 12, 1996
Appl. No.:
8/631427
Inventors:
Carl R. Merril - Rockville MD
Richard M. Carlton - Port Washington NY
Sankar L. Adhya - Gaithersburg MD
Richard M. Carlton - Port Washington NY
Sankar L. Adhya - Gaithersburg MD
Assignee:
Exponential Biotherapies, Inc. - New York NY
The United States of America as represented by the Department of Health
and Human Services - Washington DC
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
A01N 6300, C07H 2104, C12P 1934, C12N 701
US Classification:
424 936
Abstract:
The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging of a bacteriophage, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.
Antibacterial Therapy With Bacteriophage Genotypically Modified To Delay Inactivation By The Host Defense System
US Patent:
2003002, Feb 6, 2003
Filed:
Jun 19, 1997
Appl. No.:
08/879139
Inventors:
CARL R. MERRIL - ROCKVILLE MD, US
RICHARD M. CARLTON - PORT WASHINGTON NY, US
SANKAR L. ADHYA - GAITHERSBURG MD, US
RICHARD M. CARLTON - PORT WASHINGTON NY, US
SANKAR L. ADHYA - GAITHERSBURG MD, US
International Classification:
A61K039/12
US Classification:
424/093600, 424/199100
Abstract:
The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.
Antibacterial Therapy With Bacteriophage Genotypically Modified To Delay Inactivation By The Host Defense System
US Patent:
2001002, Oct 4, 2001
Filed:
May 21, 2001
Appl. No.:
09/860467
Inventors:
Carl Merril - Rockville MD, US
Richard Carlton - Port Washington NY, US
Sankar Adhya - Gaithersburg MD, US
Richard Carlton - Port Washington NY, US
Sankar Adhya - Gaithersburg MD, US
Assignee:
Exponential Biotherapies, Inc.
International Classification:
A61K048/00, C12N007/01
US Classification:
424/093210, 435/235100
Abstract:
The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.
Antibacterial Therapy With Bacteriophage Physico-Chemically Altered By Pegylation To Delay Inactivation By The Host Defense System
US Patent:
7332307, Feb 19, 2008
Filed:
Sep 11, 2003
Appl. No.:
10/659698
Inventors:
Richard M. Carlton - Port Washington NY, US
Carl R. Merril - Rockville MD, US
Sankar L. Adhya - Gaithersburg MD, US
Carl R. Merril - Rockville MD, US
Sankar L. Adhya - Gaithersburg MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
Exponential Biotherapies, Inc. - New York NY
Exponential Biotherapies, Inc. - New York NY
International Classification:
C12N 15/64
US Classification:
435 914
Abstract:
The present invention is directed to bacteriophage therapy, using methods which enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects. The HDS normally reduces the number of bacteriophage in an animal, which decreases the efficiency of the bacteriophage in killing the host bacteria present during an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes by physico-chemical alteration of the bacteriophage surface proteins, so that the altered bacteriophage remain active in the body for longer periods of time than the unmodified bacteriophage.
Antibacterial Therapy With Bacteriophage Genotypically Modified To Delay Inactivation By The Host Defense System
US Patent:
5688501, Nov 18, 1997
Filed:
Jan 29, 1996
Appl. No.:
8/593269
Inventors:
Carl R. Merril - Rockville MD
Richard M. Carlton - Port Washington NY
Sankar L. Adhya - Gaithersburg MD
Richard M. Carlton - Port Washington NY
Sankar L. Adhya - Gaithersburg MD
Assignee:
Exponential Biotherapies, Inc. - New York NY
The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC
The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC
International Classification:
A61K 3576, C12N 702, C12N 708
US Classification:
424 936
Abstract:
The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.
Antibacterial Therapy With Bacteriophage Genotypically Modified To Delay Inactiovation By The Host Defense System
US Patent:
2004016, Aug 19, 2004
Filed:
Sep 11, 2003
Appl. No.:
10/659711
Inventors:
Carl Merril - Rockville MD, US
Richard Carlton - Port Washington NY, US
Sankar Adhya - Gaithersburg MD, US
Richard Carlton - Port Washington NY, US
Sankar Adhya - Gaithersburg MD, US
International Classification:
A61K045/00
US Classification:
424/093600
Abstract:
The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.
Dr. Richard M Carlton, Port Washington NY - MD (Doctor of Medicine)
Specialties:
Psychiatry, Dietetics, Nutrition
Address:
13 S Bayles Ave, Port Washington 11050
(917) 697-4233 (Phone), (516) 767-4566 (Fax)
(917) 697-4233 (Phone), (516) 767-4566 (Fax)
Languages:
English
Education:
Medical School
New York Medical College
Graduated: 1969
New York Medical College
Graduated: 1969
Virulent Phages To Control In Foodstuffs And In Food Processing Plants
US Patent:
7438901, Oct 21, 2008
Filed:
Jul 7, 2003
Appl. No.:
10/516507
Inventors:
Martin Loessner - Binz, CH
Richard M. Carlton - Port Washington NY, US
Richard M. Carlton - Port Washington NY, US
Assignee:
Exponential Biotherapies, Inc. - Port Washington NY
International Classification:
A01N 63/00
US Classification:
424 936
Abstract:
The present invention relates to virulent (lytic) phage from the Myoviridae family, preferably P100, alone or in combination with other virulent phages. P100 and the endolysin from P100 can be administered to food products, to the components that will be added to food products, and/or to the infrastructure of the food processing plants within which such food products are processed, or the containers or wraps in which such foods are stored and/or shipped, in order to reduce contamination. P100 can also be used in the present invention to identify bacteria present on (or within) foodstuffs, as well as those bacteria present in the equipment or the general environment of the food processing plants in which the foodstuffs are being processed and in animals infected with. The phage and the endolysin of the present invention can also be used to treat animals infected with. P100 will kill the bacteria that are within its host range with great efficiency and will propagate to high titer thereon.
Virulent Phages To Detect In Foodstuffs And In Food Processing Plants
US Patent:
8034552, Oct 11, 2011
Filed:
Aug 28, 2008
Appl. No.:
12/200375
Inventors:
Martin Loessner - Binz, CH
Richard Carlton - Port Washington NY, US
Richard Carlton - Port Washington NY, US
Assignee:
E.B.I. Food Safety B.V. - Ne Den Haag
International Classification:
C12Q 1/70
US Classification:
435 5, 424 936
Abstract:
The present invention relates to virulent (lytic) phage from the Myoviridae family, preferably P100, alone or in combination with other virulent phages. P100 and the endolysin from P100 can be administered to food products, to the components that will be added to food products, and/or to the infrastructure of the food processing plants within which such food products are processed, or the containers or wraps in which such foods are stored and/or shipped, in order to reduce contamination. P100 can also be used in the present invention to identify bacteria present on (or within) foodstuffs, as well as those bacteria present in the equipment or the general environment of the food processing plants in which the foodstuffs are being processed and in animals infected with. The phage and the endolysin of the present invention can also be used to treat animals infected with. P100 will kill the bacteria that are within its host range with great efficiency and will propagate to high titer thereon.
Method For Increasing Algae Growth And The Use Thereof In Production Of Algae-Derived Biofuels And Other Chemical
US Patent:
2011026, Nov 3, 2011
Filed:
Apr 22, 2011
Appl. No.:
13/064883
Inventors:
Mark Holland - , US
Patrick Di Bello - , US
Richard M. Carlton - Port Washington NY, US
Patrick Di Bello - , US
Richard M. Carlton - Port Washington NY, US
International Classification:
C12N 1/12, A01G 1/00
US Classification:
4352576, 4352571, 47 14
Abstract:
A method of increasing yield of cultivated algae, which entails the step of cultivating one or more species of algae in the presence of one or more species of PPFM bacteria, for at least a portion of the algae cultivation.